samedan logo
 
 
spacer
home > ict > autumn 2017 > technological takeover
PUBLICATIONS
International Clinical Trials

Technological Takeover

A few simple ideas offer a new way of looking at patient reported outcomes (PROs), the healthcare industryís term for any data collected on the status of a patientís health condition that come directly from the patient. The first is that technology today has great potential to become organic and integral to a patientís physical state and lifestyle. Another is that, through this technology, information can stream directly from a patient in real time and convey health information that is comprehensive, reliable and accurate. This progression of a patientís narrative, from the patientís own senses to the patientís sensor that does the talking, promises to reshape many sectors of healthcare, from precision medicine to clinical trials.

PROs as We Know Them

Asking patients to assess their own sense of wellbeing has been a method used for many years to gather health information that can influence medical treatments and their regulatory approvals. Nonetheless, the data, such as severity of pain, nausea or sleep deprivation, can be highly variable based on individual perceptions Ė personal filters, so to speak. Factors that contribute to patient accuracy regarding adherence to treatment regimens and factors in patient recall, such as state-of-mind during an event and the time elapsed since, play a significant role in the reliability of patient-reported information. This, in turn, can make data highly subjective and less relevant than measures based on technological objectivity.

In the healthcare industry, there are standardised means of gauging the characteristics of a patientís experience. In clinical practice and research, patient-reported symptoms and quality of life issues related to disease progression or drug intake have traditionally been tracked using validated questionnaires. These assessments may be general and applicable to many diseases and interventions, or they may be specific to a single diagnosis or treatment. Further, different research institutions have developed their own validated questionnaires. Using such methods supports an approach to medical care that values the dimensions of a patient experience that have been technically unmeasurable.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jeff Beeler, Vice President of Product Innovation for IBM Clinical Development from Watson HealthTM, has over 15 years of experience in the clinical trials industry, including clinical research organisations. With expertise in SAS programming, data management and developing systems for effectively conducting clinical studies, Jeff is attuned to the challenges of bringing therapies to market and passionate about reducing barriers within clinical research.

Alysa Lesemann, Senior Writer at IBM Clinical Development from Watson HealthTM, has worked for over a decade to advance medical and science research in academia, industry and government, coordinating research programmes and writing content for organisations such as the University of North Carolina, RTI International and the National Cancer Institute. With a background in the performing arts and literature and an interest in expressing technical and personal narrative through a range of media, Alysa also holds a doctorate in biophysics from The Johns Hopkins University, US.

spacer
Jeff Beeler
spacer
spacer
spacer
Alysa Lesemann
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Prometic Bioseparations are very pleased to introduce their new purpose built ecommerce platform (Webshop)!

Their goal was to build a platform that is easy to navigate, informative and one that makes their products and services easily accessible to researchers and laboratories worldwide. They also wanted to make ordering as quick and easy as possible to meet the needs of the rapidly progressive industry. They have reflected these requirements with an ecommerce store in order to supply high quality products to customers from academia to big pharma.
More info >>

White Papers

R&D to Product: How to Reduce Costly Scale-Up Problems

Natoli Engineering Company, Inc.

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >>

 
Industry Events

Drug Discovery 2018

21-22 March 2018, Copthorne Tara Hotel, Scarsdale Place, Kensington, London

SMi Group is proud to announce the return of Drug Discovery in 2018. The successful conference will return for its 2nd year on the 21st and 22nd March.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement